BIIB
Biogen Inc
NASDAQ: BIIB · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$209.23
+1.76% today
Updated 2026-07-29
Market cap
$30.41B
P/E ratio
22.17
P/S ratio
3.06x
EPS (TTM)
$9.29
Dividend yield
—
52W range
$123 – $220
Volume
1.3M
Biogen Inc (BIIB) Insider transactions
Net insider activity
Net buying (87,608 shares)
Buy transactions
46
Sell transactions
54
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-09 | SHERWIN, STEPHEN A | Director | Buy | 1,505 | — | — |
| 2026-06-09 | ROWINSKY, ERIC K | Director | Buy | 1,505 | — | — |
| 2026-06-09 | PATOLAWALA, MONISH D | Director | Buy | 1,505 | — | — |
| 2026-06-09 | PANGALOS, MENELAS N | Director | Sale | 2,370 | — | — |
| 2026-06-09 | PANGALOS, MENELAS N | Director | Buy | 2,370 | — | — |
| 2026-06-09 | PANGALOS, MENELAS N | Director | Buy | 1,505 | — | — |
| 2026-06-09 | MINOR, LLOYD | Director | Buy | 1,505 | — | — |
| 2026-06-09 | MANTAS, JESUS B | Director | Buy | 1,505 | — | — |
| 2026-06-09 | LANGER, SUSAN | Director | Buy | 1,505 | — | — |
| 2026-06-09 | HAWKINS, WILLIAM A | Director | Buy | 1,505 | — | — |
| 2026-06-09 | FREIRE, MARIA C | Director | Buy | 2,005 | — | — |
| 2026-05-01 | KEENEY, ADAM | Head of Corporate Development | Sale | 939 | — | — |
| 2026-05-01 | KEENEY, ADAM | Head of Corporate Development | Buy | 939 | — | — |
| 2026-05-01 | KEENEY, ADAM | Head of Corporate Development | Sale | 455 | $187.06 | $85112.30 |
| 2026-04-01 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 181 | — | — |
| 2026-04-01 | GODBOUT, SEAN | Chief Accounting Officer | Buy | 181 | — | — |
| 2026-04-01 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 54 | $183.78 | $9924.12 |
| 2026-02-13 | VIEHBACHER, CHRISTOPHER | Director, President and CEO | Buy | 38,015 | — | — |
| 2026-02-13 | SINGHAL, PRIYA | Head of Development | Buy | 10,560 | — | — |
| 2026-02-13 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Buy | 10,560 | — | — |
| 2026-02-13 | KRAMER, ROBIN | Chief Financial Officer | Buy | 8,450 | — | — |
| 2026-02-13 | KEENEY, ADAM | Head of Corporate Development | Buy | 8,025 | — | — |
| 2026-02-13 | IZZAR, RACHID | Head of Global Product Strat. | Buy | 7,390 | — | — |
| 2026-02-13 | GROGAN, JANE | Head of Research | Buy | 8,450 | — | — |
| 2026-02-13 | GREGORY, GINGER | EVP, Human Resources | Buy | 8,025 | — | — |
| 2026-02-13 | GODBOUT, SEAN | Chief Accounting Officer | Buy | 1,800 | — | — |
| 2026-02-13 | ALEXANDER, SUSAN H | EVP Chief Legal Officer | Buy | 8,450 | — | — |
| 2026-02-12 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Buy | 3 | $195.04 | $585.11 |
| 2026-02-09 | SINGHAL, PRIYA | Head of Development | Sale | 2,660 | $199.83 | $531547.80 |
| 2026-02-06 | VIEHBACHER, CHRISTOPHER | Director, President and CEO | Sale | 15,453 | — | — |
| 2026-02-06 | VIEHBACHER, CHRISTOPHER | Director, President and CEO | Sale | 9,008 | — | — |
| 2026-02-06 | VIEHBACHER, CHRISTOPHER | Director, President and CEO | Buy | 15,453 | — | — |
| 2026-02-06 | VIEHBACHER, CHRISTOPHER | Director, President and CEO | Buy | 9,008 | — | — |
| 2026-02-06 | VIEHBACHER, CHRISTOPHER | Director, President and CEO | Sale | 6,624 | $201.18 | $1.33M |
| 2026-02-06 | VIEHBACHER, CHRISTOPHER | Director, President and CEO | Sale | 4,356 | $201.18 | $876340.08 |
| 2026-02-06 | SINGHAL, PRIYA | Head of Development | Sale | 4,683 | — | — |
| 2026-02-06 | SINGHAL, PRIYA | Head of Development | Sale | 2,217 | — | — |
| 2026-02-06 | SINGHAL, PRIYA | Head of Development | Buy | 4,683 | — | — |
| 2026-02-06 | SINGHAL, PRIYA | Head of Development | Buy | 2,217 | — | — |
| 2026-02-06 | SINGHAL, PRIYA | Head of Development | Sale | 1,412 | $201.18 | $284066.16 |
| 2026-02-06 | SINGHAL, PRIYA | Head of Development | Sale | 1,056 | $201.18 | $212446.08 |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Sale | 4,683 | — | — |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Sale | 2,102 | — | — |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Sale | 1,940 | — | — |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Buy | 4,683 | — | — |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Buy | 2,102 | — | — |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Buy | 1,940 | — | — |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Sale | 1,408 | $201.18 | $283261.44 |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Sale | 1,017 | $201.18 | $204600.06 |
| 2026-02-06 | MURPHY, NICOLE | Head of Pharm Ops and Tech | Sale | 914 | $201.18 | $183878.52 |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Sale | 3,511 | — | — |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Sale | 789 | — | — |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Sale | 703 | — | — |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Buy | 3,511 | — | — |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Sale | 1,063 | $201.18 | $213854.34 |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Buy | 789 | — | — |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Buy | 703 | — | — |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Sale | 273 | $201.18 | $54922.14 |
| 2026-02-06 | KRAMER, ROBIN | Chief Financial Officer | Sale | 207 | $201.18 | $41644.26 |
| 2026-02-06 | KEENEY, ADAM | Head of Corporate Development | Sale | 3,278 | — | — |
| 2026-02-06 | KEENEY, ADAM | Head of Corporate Development | Sale | 1,802 | — | — |
| 2026-02-06 | KEENEY, ADAM | Head of Corporate Development | Buy | 3,278 | — | — |
| 2026-02-06 | KEENEY, ADAM | Head of Corporate Development | Buy | 1,802 | — | — |
| 2026-02-06 | KEENEY, ADAM | Head of Corporate Development | Sale | 994 | $201.18 | $199972.92 |
| 2026-02-06 | KEENEY, ADAM | Head of Corporate Development | Sale | 589 | $201.18 | $118495.02 |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Sale | 3,043 | — | — |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Sale | 2,044 | — | — |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Sale | 1,802 | — | — |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Buy | 3,043 | — | — |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Buy | 2,044 | — | — |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Buy | 1,802 | — | — |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Sale | 805 | $201.18 | $161949.90 |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Sale | 775 | $201.18 | $155914.50 |
| 2026-02-06 | IZZAR, RACHID | Head of Global Product Strat. | Sale | 458 | $201.18 | $92140.44 |
| 2026-02-06 | GROGAN, JANE | Head of Research | Sale | 1,873 | — | — |
| 2026-02-06 | GROGAN, JANE | Head of Research | Sale | 1,385 | — | — |
| 2026-02-06 | GROGAN, JANE | Head of Research | Buy | 1,873 | — | — |
| 2026-02-06 | GROGAN, JANE | Head of Research | Buy | 1,385 | — | — |
| 2026-02-06 | GROGAN, JANE | Head of Research | Sale | 584 | $201.18 | $117489.12 |
| 2026-02-06 | GROGAN, JANE | Head of Research | Sale | 407 | $201.18 | $81880.26 |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Sale | 3,746 | — | — |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Sale | 1,802 | — | — |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Sale | 1,635 | — | — |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Buy | 3,746 | — | — |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Buy | 1,802 | — | — |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Buy | 1,635 | — | — |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Sale | 1,132 | $201.18 | $227735.76 |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Sale | 791 | $201.18 | $159133.38 |
| 2026-02-06 | GREGORY, GINGER | EVP, Human Resources | Sale | 666 | $201.18 | $133985.88 |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 517 | — | — |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 305 | — | — |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 257 | — | — |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Buy | 517 | — | — |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Buy | 305 | — | — |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Buy | 257 | — | — |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 180 | $201.18 | $36212.40 |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 103 | $201.18 | $20721.54 |
| 2026-02-06 | GODBOUT, SEAN | Chief Accounting Officer | Sale | 76 | $201.18 | $15289.68 |
| 2026-02-06 | ALEXANDER, SUSAN H | EVP Chief Legal Officer | Sale | 4,916 | — | — |
| 2026-02-06 | ALEXANDER, SUSAN H | EVP Chief Legal Officer | Sale | 2,190 | — | — |
Frequently asked questions
Are BIIB insiders buying or selling?
Over the transactions on record, BIIB insiders have been net sellers, with about $5.84M in stock sold across 54 sales, against 1 open-market purchase.
Does insider selling at BIIB mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which BIIB insiders are selling the most?
Recent selling is concentrated in a few names. VIEHBACHER, CHRISTOPHER accounts for the largest share on record, with about $2.21M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.